Primary cutaneous peripheral t-cell lymphoma with aberrant coexpression of CD20: Case report and review of the literature

American Journal of Dermatopathology

Volumn 31, Issue 2, 2009, Pages 187-192

  Balmer, Nicole N ^a,c   Hughey, Lauren ^b   Busam, Klaus J ^a   Reddy, Vishnu ^a   Andea, Aleodor A ^a  

^a University of Alabama at Birmingham   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

CD20; CD8+ lymphoma; Cutaneous T cell lymphoma

Indexed keywords

CD2 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD7 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; GRANZYME B; LEUKOSIALIN; PREDNISONE; PROTEIN TIA 1; RNA BINDING PROTEIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; UNCLASSIFIED DRUG; VINCRISTINE; BIOLOGICAL MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE LESION; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; ELECTRON THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; PAPILLEDEMA; PERIPHERAL T CELL LYMPHOMA; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUNCH BIOPSY; B LYMPHOCYTE; BIOPSY; METABOLISM; MIDDLE AGED; PATHOLOGY; REVIEW; SKIN TUMOR; T CELL LYMPHOMA; T LYMPHOCYTE;

ANTIGENS, CD20; B-LYMPHOCYTES; BIOLOGICAL MARKERS; BIOPSY; HUMANS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 67649650114     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31818cc039     Document Type: Article

References (23)

1. Buckner CL, Christiansen LR, Bourgeois D, et al. CD20 positive T-cell lymphoma/leukemia: a rare entity with potential diagnostic pitfalls. Ann Clin Lab Sci. 2007;37:263-267.
2. Mohrmann RL, Arber DA. CD20-Positive peripheral T-cell lymphoma: report of a case after nodular sclerosis Hodgkin's disease and review of the literature. Mod Pathol. 2000;13:1244-1252.
3. Quintanilla-Martinez L, Preffer F, Rubin D, et al. CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset. Am J Clin Pathol. 1994;102:483-489.
4. Sun T, Akalin A, Rodacker M, et al. CD20 positive T cell lymphoma: is it a real entity? J Clin Pathol. 2004;57:442-444.
5. Takami A, Saito M, Nakao S, et al. CD20-positive T-cell chronic lymphocytic leukaemia. Br J Haematol. 1998;102:1327-1329.
6. Warzynski MJ, Graham DM, Axtell RA, et al. Low level CD20 expression on T cell malignancies. Cytometry. 1994;18:88-92.
7. Yao X, Teruya-Feldstein J, Raffeld M, et al. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol. 2001;14:105-110.
8. Yokose N, Ogata K, Sugisaki Y, et al. CD20-positive T cell leukemia/ lymphoma: case report and review of the literature. Ann Hematol. 2001; 80:372-375.
9. Blakolmer K, Vesely M, Kummer JA, et al. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas. Mod Pathol. 2000;13:766-772.
10. Magro CM, Seilstad KH, Porcu P, et al. Primary CD20+CD10+CD8+ T-cell lymphoma of the skin with IgH and TCR beta gene rearrangement. Am J Clin Pathol. 2006;126:14-22.
11. Sen F, Kang S, Cangiarella J, et al. CD20 positive mycosis fungoides: a case report. J Cutan Pathol. 2008;35:398-403.
12. Macardle PJ, Nicholson IC. Cd20. J Biol Regul Homeost Agents. 2002;16: 136-138.
13. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87:33-43.
14. Yu K, Hu Y, Tan Y, et al. Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk Lymphoma. 2008;49:1368-1373.
15. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483-492.
16. Burg G, Kempf W, Cozzio A, et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol. 2005;32:647-674.
17. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.
18. Burg G, Kempf W. Cutaneous Lymphoma. New York, NY: Taylor and Francis; 2005.
19. Algino KM, Thomason RW, King DE, et al. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol. 1996;106: 78-81.
20. Hultin LE, Hausner MA, Hultin PM, et al. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14:196-204.
21. Hamilton-Dutoit SJ, Pallesen G. B cell associated monoclonal antibody L26 may occasionally label T cell lymphomas. APMIS. 1989;97:1033-1036.
22. Murphy M, Fullen D, Carlson JA. Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue. Am J Dermatopathol. 2002;24: 6-16.
23. van Meerten T, Claessen MJ, Hagenbeek A, et al. The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther. 2006;13:789-797.